ReviewFrontiers in immunology2026
Mechanical properties of the tumor microenvironment: drivers of immunotherapy resistance in solid tumors.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The limited efficacy of immunotherapy in solid tumors is increasingly recognized to reflect not only molecular and cellular immune suppression, but also profound mechanical abnormalities within the tumor microenvironment (TME). Emerging evidence indicates that extracellular matrix (ECM) stiffening and architectural remodeling, altered cellular stiffness, elevated solid stress, abnormal fluid shear stress, and increased interstitial fluid pressure (IFP) critically shape antitumor immunity and contribute to immunotherapy resistance. In this review, we summarize these major mechanical features and critically examine how they regulate the cancer-immunity cycle, including tumor-antigen release, antigen presentation, T-cell priming and activation, immune-cell trafficking and infiltration, tumor-cell recognition, and cytotoxic killing. We further highlight that tumor mechanical properties can function as mechanical immune checkpoints that promote immune evasion. Finally, we evaluate emerging strategies that target ECM remodeling, cancer-associated fibroblasts, vascular dysfunction, IFP, and mechanotransduction pathways to improve immunotherapy efficacy. The therapeutic evidence discussed is predominantly derived from preclinical studies. Overall, integrating tumor mechanical properties into cancer immunology provides a broader framework for understanding immunotherapy resistance and developing rational combination strategies for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.